Equity Profile

SNY

Sanofi

Health CarePharmaceuticals$105.3B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2012Pre-Market9:00 AM EDT

Company Snapshot

Sanofi (SNY) is a global healthcare company that focuses on pharmaceuticals and vaccines. With a market cap of $105 billion, it plays a significant role in the healthcare sector, addressing various medical needs and advancing treatments for chronic and rare diseases.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and will help investors gauge Sanofi's financial health this quarter.

Expected to be around $2.45

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and product offerings, which is crucial for long-term success.

Not available

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SNY Q2-2012 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+120.71%

Avg Stock Reaction

+1.51%

Last Quarter Recap

In the last quarter, Sanofi reported an EPS of $2.45, significantly beating analyst estimates by 116.64%. The stock reacted positively, gaining 2.28% the following day.

Management Promises & Guidance

Continued focus on innovation in pharmaceuticals.
Commitment to expanding vaccine production capabilities.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Sanofi's upcoming earnings, especially given its strong track record of beating EPS estimates.

Bull Case

If Sanofi continues its trend of beating EPS estimates, it could see a significant stock price increase, reflecting investor confidence in its growth strategy.

Bear Case

On the other hand, if revenue growth does not meet expectations or if there are concerns about market competition, the stock could face downward pressure.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $2.45

EPS is a key indicator of a company's profitability and will help investors gauge Sanofi's financial health this quarter.

Revenue Growth

Not available

Revenue growth reflects the company's ability to expand its market share and product offerings, which is crucial for long-term success.

Market Reaction

Average 1-day move of 3.12%

Understanding how the stock has reacted historically to earnings surprises can provide insight into potential future movements.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS this quarter?

Given Sanofi's history of beating EPS estimates, this figure will be crucial for determining market reaction.

How is Sanofi addressing competition in the pharmaceutical market?

Investors will be keen to hear about strategies to maintain market share and growth amidst increasing competition.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Sanofi's ability to leverage its recent innovations in pharmaceuticals, which could drive stronger-than-expected revenue growth.

Supporting Evidence

Sanofi has consistently beaten EPS estimates, suggesting a trend of stronger performance.

The options market is pricing a smaller move than historical averages, indicating potential for a surprise.

Recent investments in R&D may yield unexpected positive results that are not yet reflected in analyst expectations.

Key Risk

If Sanofi's EPS exceeds $2.45, it could challenge the current cautious sentiment and lead to a significant upward adjustment in stock price.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Sanofi can maintain its strong earnings performance in a competitive landscape.

Bull Confirmed If

An EPS of $2.45 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $2.20 would support the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±1.28%

Historical Avg

±3.1%

Pricing cheap

The options market is pricing in a modest move of about 1.28%, indicating that investors expect limited volatility around the earnings announcement.

Options are pricing ±1.3% while SNY has averaged ±3.1% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.3%

30d HV

25.3%

Calls (55K)P/C Ratio: 0.34Puts (44K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Sanofi beats expectations, history suggests the stock could rise by around 1.51%, confirming investor confidence in its growth strategy.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further commentary from management.

Miss

If the company misses expectations, history suggests a potential decline of around 3.12%, which could raise concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Insights into cost management strategies and their effect on margins.
3Details on vaccine production capacity and demand trends.
4Management's outlook on competitive pressures in the pharmaceutical sector.
5Any commentary on future R&D initiatives and their timelines.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and will help investors gauge Sanofi's financial health this quarter.

Expected to be around $2.45

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and product offerings, which is crucial for long-term success.

Not available

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SNY Q2-2012 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+120.71%

Avg Stock Reaction

+1.51%

Last Quarter Recap

In the last quarter, Sanofi reported an EPS of $2.45, significantly beating analyst estimates by 116.64%. The stock reacted positively, gaining 2.28% the following day.

Management Promises & Guidance

Continued focus on innovation in pharmaceuticals.
Commitment to expanding vaccine production capabilities.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Sanofi's upcoming earnings, especially given its strong track record of beating EPS estimates.

Bull Case

If Sanofi continues its trend of beating EPS estimates, it could see a significant stock price increase, reflecting investor confidence in its growth strategy.

Bear Case

On the other hand, if revenue growth does not meet expectations or if there are concerns about market competition, the stock could face downward pressure.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $2.45

EPS is a key indicator of a company's profitability and will help investors gauge Sanofi's financial health this quarter.

Revenue Growth

Not available

Revenue growth reflects the company's ability to expand its market share and product offerings, which is crucial for long-term success.

Market Reaction

Average 1-day move of 3.12%

Understanding how the stock has reacted historically to earnings surprises can provide insight into potential future movements.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS this quarter?

Given Sanofi's history of beating EPS estimates, this figure will be crucial for determining market reaction.

How is Sanofi addressing competition in the pharmaceutical market?

Investors will be keen to hear about strategies to maintain market share and growth amidst increasing competition.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Sanofi's ability to leverage its recent innovations in pharmaceuticals, which could drive stronger-than-expected revenue growth.

Supporting Evidence

Sanofi has consistently beaten EPS estimates, suggesting a trend of stronger performance.

The options market is pricing a smaller move than historical averages, indicating potential for a surprise.

Recent investments in R&D may yield unexpected positive results that are not yet reflected in analyst expectations.

Key Risk

If Sanofi's EPS exceeds $2.45, it could challenge the current cautious sentiment and lead to a significant upward adjustment in stock price.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Sanofi can maintain its strong earnings performance in a competitive landscape.

Bull Confirmed If

An EPS of $2.45 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $2.20 would support the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±1.28%

Historical Avg

±3.1%

Pricing cheap

The options market is pricing in a modest move of about 1.28%, indicating that investors expect limited volatility around the earnings announcement.

Options are pricing ±1.3% while SNY has averaged ±3.1% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.3%

30d HV

25.3%

Calls (55K)P/C Ratio: 0.34Puts (44K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Sanofi beats expectations, history suggests the stock could rise by around 1.51%, confirming investor confidence in its growth strategy.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further commentary from management.

Miss

If the company misses expectations, history suggests a potential decline of around 3.12%, which could raise concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Insights into cost management strategies and their effect on margins.
3Details on vaccine production capacity and demand trends.
4Management's outlook on competitive pressures in the pharmaceutical sector.
5Any commentary on future R&D initiatives and their timelines.